眼科用医薬品市場：ディスペンスタイプ、疾患、製品タイプ、剤形、流通別-2025-2030年の世界予測

眼科用医薬品市場は、2023年に289億9,000万米ドルと評価され、2024年には305億6,000万米ドルに達すると予測され、CAGR 5.86%で成長し、2030年には432億1,000万米ドルになると予測されています。

360iResearchの眼科用医薬品にフォーカスした市場調査アナリストである本調査の調査対象範囲は、緑内障、ドライアイ症候群、網膜疾患、感染症など、様々な眼疾患の治療に使用される薬剤を網羅しています。これらの薬剤は、眼の解剖学的構造および機能に影響を及ぼす疾患に対処することを目的とした点眼薬、軟膏、経口錠剤など複数の形態があります。眼科用医薬品の必要性は、人口の高齢化、スクリーン使用時間の増加、目の健康に対する意識の高まりにより、眼疾患の有病率が上昇していることに起因しています。様々な用途が治療と予防の両方に適用されるため、これらの医薬品は病院薬局、小売薬局、オンライン・チャネルにおいて極めて重要です。市場の成長は、ドラッグデリバリーシステムの技術的進歩、低侵襲治療に対する需要の増加、製品ポートフォリオを拡大するための主要企業間の戦略的提携によって大きく左右されます。

最新のビジネスチャンスは、ゲノミクスを活用して個々の患者プロファイルに特化した治療を行う個別化医療の開発や、患者のアドヒアランスと有効性を高める徐放性ドラッグデリバリーシステムの革新にあります。企業は、ヘルスケア・インフラが拡大するアジア太平洋のような新興市場に参入することで、注目すべき成長の可能性を見出すことができます。しかし、厳しい規制のハードルと先進的な治療薬の高コストが参入障壁となり、新薬の承認を抑制する可能性があります。また、偽造医薬品がブランドの信頼性に影響を与えるという課題にも直面しています。

イノベーションは、これまで治療不可能であった病態を治療する新たな道筋を提供する遺伝子治療と生物製剤のブレークスルーに焦点を当てるべきです。眼科マイクロバイオームと全身性疾患との関連性を探る研究開発努力が加速すれば、新たな治療フロンティアが開ける可能性があります。眼科用医薬品市場はダイナミックな性質を持っており、緩やかな成長軌道から急成長軌道にあり、品質と患者の転帰による差別化が重視されています。患者中心のニーズを理解し、それに応じて製品パイプラインを最適化することは、この進化する情勢において事業の持続的成長と競合優位性を確保する上で極めて重要です。

市場力学：急速に進化する眼科用医薬品市場における主要市場インサイトの解明

眼科用医薬品市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 眼科疾患および適応症の世界の増加
  • 眼科疾患治療のための併用療法の開発拡大
  • 認知度、治療へのアクセス、薬剤の入手可能性の向上
• 市場抑制要因
  • 高い開発コストと研究開発に要する時間
• 市場機会
  • 新規眼科用医薬品開発のためのベンダーによる投資と研究開発活動の増加
  • 眼科用生物製剤における大きな可能性
• 市場の課題
  • 眼科用医薬品の監視されていない副作用

ポーターの5つの力：眼科用医薬品市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：眼科用医薬品市場における外部からの影響の把握

外部マクロ環境要因は、眼科用医薬品市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析眼科用医薬品市場における競合情勢の把握

眼科用医薬品市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス眼科用医薬品市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、眼科用医薬品市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨眼科用医薬品市場における成功への道筋を描く

眼科用医薬品市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界的に眼科疾患および適応症の有病率が上昇
    • 眼科治療における併用療法の開発が進む

障害

• 認知度の向上、治療へのアクセス、薬剤の入手しやすさ
• 抑制要因
  • 開発コストが高く、眼科用医薬品の研究開発に時間がかかる
• 機会
  • 新規開発に向けたベンダーによる投資と研究開発活動の増加眼科用医薬品
  • 眼科用生物製剤における大きな可能性
• 課題
  • 眼科用医薬品の監視されていない副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 眼科用医薬品市場ディスペンスタイプ別

• 店頭
• 処方箋

第7章 眼科用医薬品市場病状別

• アレルギー
• ドライアイ障害
• 緑内障
• 網膜疾患
  • 糖尿病網膜症
  • ドライ型加齢黄斑変性
  • 滲出型加齢黄斑変性

第8章 眼科用医薬品市場：製品別

• カプセルとタブレット
• ドロップ
• ジェル
• 軟膏
• ソリューションとサスペンション

第9章 眼科用医薬品市場剤形別

• 液体点眼薬
• マルチコンパートメントドラッグデリバリーシステム
• 半固形点眼薬
• 固形点眼薬

第10章 眼科用医薬品市場配布元

• ドラッグストア
• 病院薬局
• オンライン薬局

第11章 南北アメリカの眼科用医薬品市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の眼科用医薬品市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの眼科用医薬品市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ボシュロム、XIIDRAの買収を計画
  • FDA、ノバリック社のシクロスポリン点眼液をドライアイ治療として承認
  • EyenoviaとFormosaが新たな眼科治療薬の開発で提携
  • リヴァナ、持続放出型眼内インプラントの開発に1,200万米ドルを調達
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Alcon Vision LLC
• Allergan PLC by AbbVie Inc.
• Apotex Inc.
• Bausch Health Companies Inc.
• Bayer AG
• Carl Zeiss AG
• Coherus Biosciences, Inc.
• EyePoint Pharmaceuticals, Inc.
• Eyevensys
• Genentech, Inc.
• Johnson & Johnson Service, Inc.
• Kodiak Sciences Inc.
• Lupin Limited
• Merck & Co.
• Nicox SA
• Novaliq GmbH
• Novartis AG
• Ocular Therapeutix, Inc.
• OCuSOFT Inc.
• Pfizer Inc.
• Recipharm AB
• Regeneron Pharmaceuticals, Inc.
• Santen Pharmaceutical Co., Ltd.
• Senju Pharmaceutical Co., Ltd.
• Somerset Pharma, LLC.
• Sun Pharmaceutical Industries, Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

LIST OF FIGURES

• FIGURE 1. OPHTHALMIC DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. OPHTHALMIC DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. OPHTHALMIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. OPHTHALMIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. OPHTHALMIC DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. OPHTHALMIC DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ALLERGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRY EYE DISORDER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY CAPSULES & TABLETS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DROPS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY SOLUTIONS & SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY LIQUID OPHTHALMIC DRUG FORMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY MULTICOMPARTMENT DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY SEMISOLID OPHTHALMIC DRUG FORMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY SOLID OPHTHALMIC DRUG FORMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 53. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 54. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 55. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 56. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 57. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 58. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 79. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 80. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 85. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 86. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 87. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 88. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 89. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 90. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 91. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 92. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 93. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 94. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 95. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 96. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 97. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 98. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 102. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 103. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 104. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 108. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 109. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 110. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 114. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 115. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 116. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 120. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 121. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 126. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 133. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 138. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 139. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 144. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 145. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 150. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 158. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 163. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 164. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 165. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 169. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 170. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 171. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 175. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 176. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 177. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 181. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 182. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 183. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 187. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 188. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 189. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 193. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 194. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 195. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 196. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 197. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 198. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 199. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 200. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 201. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 205. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 206. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 207. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 211. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 212. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 213. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 217. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 218. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 219. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 220. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 221. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 222. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 223. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 224. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 225. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 226. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 227. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 228. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 229. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 230. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 231. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 235. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 236. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 248. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 249. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 253. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 254. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 255. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 259. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 260. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 261. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 265. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 266. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 267. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 271. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 278. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
• TABLE 284. OPHTHALMIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 285. OPHTHALMIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Ophthalmic Drugs Market was valued at USD 28.99 billion in 2023, expected to reach USD 30.56 billion in 2024, and is projected to grow at a CAGR of 5.86%, to USD 43.21 billion by 2030.

As a Market Research Analyst focusing on Ophthalmic Drugs at 360iResearch, the scope of the study encompasses drugs used to treat various eye disorders, including glaucoma, dry eye syndrome, retinal disorders, and infections. These drugs come in multiple forms such as eye drops, ointments, and oral tablets aimed at addressing diseases affecting the eye's anatomy and functionality. The necessity for ophthalmic drugs is driven by the rising prevalence of eye conditions due to the aging population, increased screen time, and growing awareness about eye health. Various applications apply to both therapeutic and preventive care, making these drugs crucial across hospital pharmacies, retail pharmacies, and online channels. Market growth is significantly influenced by technological advancements in drug delivery systems, the increasing demand for minimally invasive treatments, and strategic partnerships among key players to expand product portfolios.

Latest opportunities reside in the development of personalized medicine, which harnesses genomics to tailor treatments specific to individual patient profiles, and innovations in sustained-release drug delivery systems that enhance patient adherence and efficacy. Companies can tap into emerging markets like Asia-Pacific, where expanding healthcare infrastructure presents notable growth potential. However, stringent regulatory hurdles and the high cost of advanced therapies pose barriers to entry and can curtail new drug approvals. The market also faces challenges with counterfeit drugs impacting brand integrity.

Innovation should focus on breakthroughs in gene therapy and biologics that offer new pathways for treating previously untreatable conditions. Accelerated R&D efforts in exploring the ocular microbiome and its correlations with systemic diseases could open new therapeutic frontiers. The ophthalmic drug market exemplifies a dynamic nature, with a moderate to fast-growth trajectory and a strong emphasis on differentiation through quality and patient outcomes. Understanding patient-centric needs and optimizing product pipelines accordingly will be pivotal for sustained business growth and competitive advantage in this evolving landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Ophthalmic Drugs Market

The Ophthalmic Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rise in the prevalence of ophthalmic disorders and indications globally
  • Growing development combination therapies for the treatment of ophthalmic disorders
  • Increased awareness, treatment accessibility and drug availability
• Market Restraints
  • High development costs and time taking research and development of ophthalmic drugs
• Market Opportunities
  • Increasing investment and R&D activities by vendors to develop novel ophthalmic drugs
  • Significant potential in ophthalmic biologics
• Market Challenges
  • Unmonitored side effects of ophthalmic drugs

Porter's Five Forces: A Strategic Tool for Navigating the Ophthalmic Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Ophthalmic Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Ophthalmic Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Ophthalmic Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Ophthalmic Drugs Market

A detailed market share analysis in the Ophthalmic Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Ophthalmic Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Ophthalmic Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Ophthalmic Drugs Market

A strategic analysis of the Ophthalmic Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Ophthalmic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alcon Vision LLC, Allergan PLC by AbbVie Inc., Apotex Inc., Bausch Health Companies Inc., Bayer AG, Carl Zeiss AG, Coherus Biosciences, Inc., EyePoint Pharmaceuticals, Inc., Eyevensys, Genentech, Inc., Johnson & Johnson Service, Inc., Kodiak Sciences Inc., Lupin Limited, Merck & Co., Nicox SA, Novaliq GmbH, Novartis AG, Ocular Therapeutix, Inc., OCuSOFT Inc., Pfizer Inc., Recipharm AB, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., Somerset Pharma, LLC., Sun Pharmaceutical Industries, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Ophthalmic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Dispense Type, market is studied across Over the Counter and Prescription.
• Based on Disease Condition, market is studied across Allergy, Dry Eye Disorder, Glaucoma, and Retinal Disorder. The Retinal Disorder is further studied across Diabetic Retinopathy, Dry Age-related Macular Degeneration, and Wet Age-related Macular Degeneration.
• Based on Products, market is studied across Capsules & Tablets, Drops, Gels, Ointments, and Solutions & Suspensions.
• Based on Dosage Form, market is studied across Liquid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, Semisolid Ophthalmic Drug Forms, and Solid Ophthalmic Drug Forms.
• Based on Distribution, market is studied across Drug Stores, Hospital Pharmacies, and Online Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in the prevalence of ophthalmic disorders and indications globally
    • 5.1.1.2. Growing development combination therapies for the treatment of ophthalmic

disorders

• 5.1.1.3. Increased awareness, treatment accessibility and drug availability
• 5.1.2. Restraints
  • 5.1.2.1. High development costs and time taking research and development of ophthalmic drugs
• 5.1.3. Opportunities
  • 5.1.3.1. Increasing investment and R&D activities by vendors to develop novel ophthalmic drugs
  • 5.1.3.2. Significant potential in ophthalmic biologics
• 5.1.4. Challenges
  • 5.1.4.1. Unmonitored side effects of ophthalmic drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Ophthalmic Drugs Market, by Dispense Type

• 6.1. Introduction
• 6.2. Over the Counter
• 6.3. Prescription

7. Ophthalmic Drugs Market, by Disease Condition

• 7.1. Introduction
• 7.2. Allergy
• 7.3. Dry Eye Disorder
• 7.4. Glaucoma
• 7.5. Retinal Disorder
  • 7.5.1. Diabetic Retinopathy
  • 7.5.2. Dry Age-related Macular Degeneration
  • 7.5.3. Wet Age-related Macular Degeneration

8. Ophthalmic Drugs Market, by Products

• 8.1. Introduction
• 8.2. Capsules & Tablets
• 8.3. Drops
• 8.4. Gels
• 8.5. Ointments
• 8.6. Solutions & Suspensions

9. Ophthalmic Drugs Market, by Dosage Form

• 9.1. Introduction
• 9.2. Liquid Ophthalmic Drug Forms
• 9.3. Multicompartment Drug Delivery Systems
• 9.4. Semisolid Ophthalmic Drug Forms
• 9.5. Solid Ophthalmic Drug Forms

10. Ophthalmic Drugs Market, by Distribution

• 10.1. Introduction
• 10.2. Drug Stores
• 10.3. Hospital Pharmacies
• 10.4. Online Pharmacies

11. Americas Ophthalmic Drugs Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Ophthalmic Drugs Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Ophthalmic Drugs Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Bausch + Lomb Plans to Acquire XIIDRA
  • 14.3.2. FDA Approves Novaliq's Cyclosporine Ophthalmic Solution For Treatment Of Dry Eye Disease
  • 14.3.3. Eyenovia and Formosa Partner For New Ophthalmic Therapeutics
  • 14.3.4. Re-Vana Reels in USD 12M To Develop Sustained-Release Eye Implants
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Alcon Vision LLC
• 3. Allergan PLC by AbbVie Inc.
• 4. Apotex Inc.
• 5. Bausch Health Companies Inc.
• 6. Bayer AG
• 7. Carl Zeiss AG
• 8. Coherus Biosciences, Inc.
• 9. EyePoint Pharmaceuticals, Inc.
• 10. Eyevensys
• 11. Genentech, Inc.
• 12. Johnson & Johnson Service, Inc.
• 13. Kodiak Sciences Inc.
• 14. Lupin Limited
• 15. Merck & Co.
• 16. Nicox SA
• 17. Novaliq GmbH
• 18. Novartis AG
• 19. Ocular Therapeutix, Inc.
• 20. OCuSOFT Inc.
• 21. Pfizer Inc.
• 22. Recipharm AB
• 23. Regeneron Pharmaceuticals, Inc.
• 24. Santen Pharmaceutical Co., Ltd.
• 25. Senju Pharmaceutical Co., Ltd.
• 26. Somerset Pharma, LLC.
• 27. Sun Pharmaceutical Industries, Inc.
• 28. Takeda Pharmaceutical Company Limited
• 29. Teva Pharmaceutical Industries Ltd.
• 30. Viatris Inc.